Compare GLND & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLND | ONCY |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Pharmaceuticals and Biotechnology |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 107.3M |
| IPO Year | N/A | 2002 |
| Metric | GLND | ONCY |
|---|---|---|
| Price | $2.33 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $0.77 |
| 52 Week High | $12.80 | $1.51 |
| Indicator | GLND | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 45.25 |
| Support Level | N/A | $0.81 |
| Resistance Level | $3.26 | $1.06 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 58.18 | 22.15 |
Greenland Energy Co is a Texas energy resources company focused on unlocking Greenland's vast hydrocarbon potential through the application of modern exploration technologies. It holds exclusive licenses to over 2-million acre area in the Jameson Land Basin, where its licenses cover the majority of the basin. The business model for the company is based on exploration and resource development in the frontier basins of Greenland. The company's primary focus is drilling the first wells on the project to conduct the necessary exploration, appraisal and evaluation.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.